Stage II Ovarian Cancer

2

Review clinical trials related to Stage II Ovarian Cancer. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Recruiting

A Study Comparing Perioperative Stress Reduction vs. Standard of Care in Ovarian Cancer (PRESERVE)

The purpose of this study is to see if propranolol and etodolac along with mind-body resilience training/MBRT and music therapy help participants who are experiencing physiological stress before, during, and after primary debulking surgery/PDS or IDS and also if it's better than the standard-of-care approach (no intervention for reducing stress).

Participants needed: 35
Trial details
Age: 18+Biological sex: FemaleType: InterventionalSponsor: Memorial Sloan Kettering Cancer CenterUpdated: Jul 1, 2026Locations: 7
Eligibility criteria

Advanced (stage II-IV) epithelial ovarian, fallopian tube, or primary peritoneal... [+5]

Chronic treatment with any β-blocker or COX inhibitor [+8]

Status: Recruiting

Developing a Test of Uterine Lavage for the Detection of Ovarian Cancer

The study aims to develop a test for early detection of ovarian cancer using DNA from a growth involving the ovary found in a washing of the uterus (womb), and proteins found in the blood. The samples of the wash and the blood will be taken before surgery. After surgery, doctors will determine whether the participant had ovarian cancer or a benign disease of the ovaries. The tests of the washings and the blood will be examined to see how much the participants with ovarian cancer can be separated from the participants with a benign ovarian disease by the tests. Small amounts from the washing and the blood samples will be sent to four sites for analysis. Statistical analyses of these data will compare tumor DNA found in the washing of the uterus with proteins in the blood to detect cases of ovarian cancer. The primary goal is to find tests that are mostly positive for cases of ovarian cancer and mostly negative for patients with benign disease. It is hoped that if the tests work for participants with symptoms of the disease that these tests will also work when testing women who have no symptoms. A new study would be needed to see if the tests worked in this situation. If the tests work, this could lead to increasing the number of cases detected in early stage disease and decreasing the number of cases detected in late stage disease. If this change in late stage is large, it will likely reduce deaths due to ovarian cancer.

Participants needed: 250
Trial details
Age: 30+Biological sex: FemaleType: ObservationalSponsor: Massachusetts General HospitalUpdated: Sep 16, 2025Locations: 6
Eligibility criteria

Has intact uterus (no history of uterine ablation, tubal ligation or bilateral s... [+2]

Current tissue or cytology diagnostic procedure positive for ovary cancer or any... [+11]